1.. Introduction
================

Coronary artery disease (CAD) also known as coronary heart disease (CHD), is the leading cause of death and disability worldwide \[[@b1-ijms-15-07987],[@b2-ijms-15-07987]\]. CAD is associated with genetic and environmental factors, as well as their interactions \[[@b3-ijms-15-07987]\]. Confirmed risk factors for CAD include hypercholesterolemia, hypertension, smoking, and diabetes \[[@b4-ijms-15-07987]\]. However, in addition to modifiable risk factors, genetic factors can also predispose individuals to CAD. It has been estimated that genetic risk factors explain approximately 20%--60% of CAD cases \[[@b5-ijms-15-07987]\].

Nitric oxide (NO) is an important atheroprotective mediator that helps mediate endothelium-dependent vasodilatation. Abnormalities in NO generation could play an important role in the pathophysiology of CAD \[[@b6-ijms-15-07987]\]. NO is synthesized from [l]{.smallcaps}-arginine by the action of nitric oxide synthase (NOS). There are at least three isoenzymes of NOS: inducible NOS, neuronal NOS, and endothelial NOS (eNOS) \[[@b7-ijms-15-07987]\]. The *eNOS* gene is located on chromosome 7q35--q36 and is sized 21 kilobases (kb) \[[@b8-ijms-15-07987]\]. A number of studies have suggested that polymorphisms in the *eNOS* gene affected NO availability and were associated with CAD morbidity. One of the most clinically relevant *eNOS* variants forms 27-basepair (bp) tandem repeats in *intron 4 (4b/a).* The *eNOS 4b* allele contains five repeats of the 27 bp sequence, whereas *eNOS 4a*, which is the rare allele, carries a deletion of one of the first three of these repeats \[[@b9-ijms-15-07987]\].

The association between *eNOS 4b/a* gene polymorphisms and CAD remains controversial, and the results of two previous meta-analyses were inconsistent \[[@b10-ijms-15-07987],[@b11-ijms-15-07987]\]. In 2004, Casas *et al.* performed a meta-analysis of 16 studies and found an increased risk of ischemic heart disease (IHD) in individuals carrying the homozygous a allele compared with the b allele \[[@b10-ijms-15-07987]\]. However, a subsequent meta-analysis in 2010 reported conflicting data, where *eNOS 4b/a* did not significantly increase the risk of developing CAD \[[@b11-ijms-15-07987]\]. A large number of new case-control studies assessing the association between *eNOS 4b/a* polymorphisms and the CAD risk have been published since 2010. Therefore, we performed a meta-analysis using a more complete database to clarify the association between *eNOS 4b/a* polymorphisms and CAD risk.

2.. Results and Discussion
==========================

2.1.. Characteristics of Included Studies
-----------------------------------------

A total of 373 papers were initially identified during the literature search and from other sources; 37 of these met the inclusion criteria for this analysis \[[@b9-ijms-15-07987],[@b12-ijms-15-07987]--[@b47-ijms-15-07987]\]. A flow chart describing the literature search and study identification is shown in [Figure 1](#f1-ijms-15-07987){ref-type="fig"}. The meta-analysis of the *4b/a* polymorphism included 10,617 CAD cases and 8302 controls. The study characteristics are summarized in [Table 1](#t1-ijms-15-07987){ref-type="table"}. The number of subjects in the studies varied considerably (range from 40 to 1265 in the case group and from 34 to 620 in the control group). Among the 37 case-control studies, 11 studies included Asian population \[[@b15-ijms-15-07987]--[@b25-ijms-15-07987]\], and 26 assessed non-Asians \[[@b9-ijms-15-07987],[@b12-ijms-15-07987]--[@b14-ijms-15-07987],[@b26-ijms-15-07987]--[@b47-ijms-15-07987]\]. Controls were mainly matched in terms of gender and age. Fourteen studies were hospital-based \[[@b16-ijms-15-07987]--[@b18-ijms-15-07987],[@b20-ijms-15-07987],[@b21-ijms-15-07987],[@b25-ijms-15-07987],[@b28-ijms-15-07987],[@b37-ijms-15-07987]--[@b40-ijms-15-07987],[@b42-ijms-15-07987],[@b43-ijms-15-07987],[@b45-ijms-15-07987]\], and 20 were population-based \[[@b9-ijms-15-07987],[@b12-ijms-15-07987]--[@b15-ijms-15-07987],[@b19-ijms-15-07987],[@b22-ijms-15-07987],[@b23-ijms-15-07987],[@b26-ijms-15-07987],[@b27-ijms-15-07987],[@b29-ijms-15-07987]--[@b34-ijms-15-07987],[@b36-ijms-15-07987],[@b41-ijms-15-07987],[@b46-ijms-15-07987],[@b47-ijms-15-07987]\]. Thirty studies were performed using \<500 subjects in the case group \[[@b12-ijms-15-07987]--[@b27-ijms-15-07987],[@b29-ijms-15-07987],[@b33-ijms-15-07987]--[@b36-ijms-15-07987],[@b38-ijms-15-07987]--[@b47-ijms-15-07987]\] and 33 were conducted with \<500 subjects in the control group \[[@b9-ijms-15-07987],[@b12-ijms-15-07987]--[@b15-ijms-15-07987],[@b17-ijms-15-07987]--[@b29-ijms-15-07987],[@b32-ijms-15-07987],[@b34-ijms-15-07987]--[@b47-ijms-15-07987]\]. Furthermore, there were 20 studies of CAD \[[@b9-ijms-15-07987],[@b18-ijms-15-07987],[@b20-ijms-15-07987],[@b22-ijms-15-07987],[@b23-ijms-15-07987],[@b25-ijms-15-07987],[@b29-ijms-15-07987],[@b30-ijms-15-07987],[@b32-ijms-15-07987],[@b34-ijms-15-07987]--[@b40-ijms-15-07987],[@b42-ijms-15-07987]--[@b44-ijms-15-07987],[@b46-ijms-15-07987]\], four of CHD \[[@b17-ijms-15-07987],[@b26-ijms-15-07987]--[@b28-ijms-15-07987]\], three of acute myocardial infarction \[[@b15-ijms-15-07987],[@b19-ijms-15-07987],[@b45-ijms-15-07987]\], six of myocardial infarction (MI) \[[@b12-ijms-15-07987]--[@b14-ijms-15-07987],[@b16-ijms-15-07987],[@b31-ijms-15-07987],[@b41-ijms-15-07987]\], and four of acute coronary syndrome \[[@b21-ijms-15-07987],[@b24-ijms-15-07987],[@b33-ijms-15-07987],[@b47-ijms-15-07987]\].

2.2.. Meta-Analysis Results
---------------------------

The relationship between *eNOS 4b/a* polymorphisms and CAD risk are summarized in [Table 2](#t2-ijms-15-07987){ref-type="table"}. Overall, significant positive associations between CAD risk and *eNOS 4b/a* polymorphism were identified in the homozygote comparison (*aa vs. bb*, OR = 1.47, 95% CI = 1.16--1.87, *p*~heterogeneity~ = 0.085), the heterozygote comparison (*ab vs. bb*, OR = 1.14, 95% CI = 1.02--1.27, *p*~heterogeneity~ \< 0.001) and the dominant model (*ab* + *aa vs. bb*, OR = 1.18, 95% CI = 1.06--1.33, *p*~heterogeneity~ \< 0.001).

In a stratified analysis by the source of the control population, significantly increased CAD risk was detected in the population-based subgroup of all the three genetic models (OR = 1.64, 95% CI = 1.18--2.27, *p* = 0.070 for the homozygote comparison; OR = 1.16, 95% CI = 1.00--1.35, *p* \< 0.001 for the heterozygote comparison; and OR = 1.21, 95% CI = 1.05--1.40, *p* \< 0.001 for the dominant model). There was no significantly increased CAD risk in the hospital-based subgroup (OR = 1.11, 95% CI =0.78--1.56, *p* = 0.509 for the homozygote comparison; OR = 1.04, 95% CI = 0.88--1.23, *p* = 0.072 for the heterozygote comparison; and OR = 1.07, 95% CI = 0.89--1.27, *p* = 0.027 in the dominant model) ([Figure 2](#f2-ijms-15-07987){ref-type="fig"}).

The data were also stratified into Asian and non-Asian subpopulations. There was a statistically significant association in the non-Asian subgroup in the homozygote comparison (OR = 1.41, 95% CI = 1.08--1.84, *p* = 0.080) and the dominant model (OR = 1.16, 95% CI = 1.02--1.32, *p* \< 0.001). Non-Asians were then further stratified into Caucasians, Africans, and others. The populations of an American study and a Brazilian study were both composed of two ethnicities: Caucasians and Africans \[[@b39-ijms-15-07987],[@b40-ijms-15-07987]\]. The different ethnic descents in these studies were considered to be two independent studies during sub-stratified analyses. Statistically significant associations were noted in African populations in three genetic models (homozygote comparison OR = 2.93, 95% CI = 1.71--5.03, *p* = 0.821; heterozygote comparison OR = 1.46, 95% CI = 1.16--1.83, *p* = 0.353; and the dominant model OR = 1.58, 95% CI = 1.27--1.96, *p =* 0.370). Interestingly, significant associations were also found in Asian (OR = 1.82, 95% CI = 1.03--3.20, *p* = 0.316) and "other" (OR = 2.65, 95% CI = 1.37--5.13, *p* = 0.369) populations during the homozygote comparison. In contrast, no statistically significant associations were identified in Caucasian populations (OR = 1.03, 95% CI = 0.80--1.31, *p* = 0.621 in the homozygote comparison; OR = 1.04, 95% CI = 0.90--1.20, *p* = 0.006 in the heterozygote comparison; OR = 1.04, 95% CI = 0.91--1.19, *p* = 0.007 in the dominant model) ([Supplementary Figure S1](#s1-ijms-15-07987){ref-type="supplementary-material"}).

The data were then also stratified according to case sample size into large (\>500 total cases) and small-and-moderate case sample (\<500 total cases) subgroups. Significant associations between *eNOS 4b/a* polymorphisms and CAD risk were observed in the small-and-moderate case sample subgroup (OR = 1.75, 95% CI = 1.35--2.28, *p* = 0.262 in the homozygote comparison; OR = 1.20, 95% CI = 1.07--1.35, *p* = 0.011 in the heterozygote comparison; and OR = 1.26, 95% CI = 1.11--1.42, *p* = 0.002 in the dominant model) but not in the large case sample subgroup. The data were then stratified into large control (\>500 control individuals) and small-and-moderate control sample (\<500 control individuals) subgroups. Similar to the data from the case sample size analyses, significant associations were observed in the small-and-moderate control sample subgroup (OR = 1.56, 95% CI = 1.19--2.05, *p* = 0.113 for the homozygote comparison; OR = 1.15, 95% CI = 1.01--1.31, *p* \< 0.001 for the heterozygote comparison; and OR = 1.20, 95% CI = 1.06--1.36, *p* \< 0.001 in the dominant model), but not the large case sample subgroup.

Finally, a subgroup analysis for MI was performed. There were significant associations between *eNOS 4b/a* polymorphisms and CAD risk with the homozygote comparison (OR = 2.30, 95% CI = 1.17--4.51, *p* = 0.020), heterozygote comparison (OR = 1.42, 95% CI = 1.07--1.89, *p* = 0.002), and dominant model (OR = 1.50, 95% CI = 1.09--2.07, *p* \< 0.001) in patients with MI.

2.3.. Evaluation of Heterogeneity
---------------------------------

There was minor heterogeneity among studies in the recessive model (*ab* + *bb vs. aa*, *p*~heterogeneity~ = 0.213, *I*^2^ = 15.4%), while the results of heterogeneity tests were significant in the other three genetic models (*aa vs. bb*, *p*~heterogeneity~ = 0.085, *I*^2^ = 25.5%; *ab vs bb*, *p*~heterogeneity~ \< 0.001, *I*^2^ = 56.7%; *ab* + *aa vs. bb*, *p*~heterogeneity~ \< 0.001, *I*^2^ = 61.1%). The random-effects models were used in all the four genetic models. Meta-regression analyses were then performed to evaluate the extent to which different variables explained the heterogeneity. The results revealed that the heterogeneity could be explained by case sample size (*p* = 0.015) and total sample size (*p* = 0.015) in the homozygote comparison. However, population ethnicity, year of publication, source of control population, total sample size, and outcome were not statistically correlated with heterogeneity (*p* \> 0.05).

2.4.. Sensitivity Analysis and Publication Bias
-----------------------------------------------

Sensitivity analysis was performed by omitting one study at a time. No significant differences in the data were observed, indicating that the results were statistically reliable ([Supplementary Figure S2](#s1-ijms-15-07987){ref-type="supplementary-material"}). The publication bias of the studies was assessed by performing the Begg's funnel plot and Egger's test. There was no obvious publication bias in the heterozygote comparison (*ab vs. bb*, Begg's test *p* = 0.754, Egger's test *p* = 0.473), and the dominant model (*ab* + *aa vs. bb*, Begg's test *p* = 0.619, Egger's test *p* = 0.274). The shape of the funnel plot for the homozygote comparison appeared to be approximately asymmetrical, which was confirmed by the test results (*aa vs. bb*, Begg's test *p* = 0.022, Egger's test *p* = 0.004). However, adjusting the model by the trim and fill method did not influence the conclusions (OR = 1.23, 95% CI = 1.02--1.48) ([Figure 3](#f3-ijms-15-07987){ref-type="fig"}).

2.5.. Discussion
----------------

The meta-analysis revealed that *eNOS 4b/a* polymorphisms were significantly associated with CAD in three genetic models (dominant model, homozygote comparison, and heterozygote comparison). These data suggest that carriers of the *a* allele of the *eNOS 4b/a* gene might be predisposed to CAD. Heterogeneity was observed in these three models; however, subsequent meta-regression analyses revealed that case and total sample size could explain the heterogeneity. Subgroup analysis based on source of the control population revealed that population-based subgroups with the *aa* or *ab* genotypes had a significantly increased risk of CAD. In stratified analyses according to ethnicity, significantly increased risk was detected in the African subgroup with the *aa* or *ab* genotypes and the Asian subgroup with the *aa* genotype. Positive associations were also identified in studies whose case or control sample size was \<500 with the *aa* or *ab* genotypes. Similarly, significant associations were identified in studies with the *aa* or *ab* genotypes in a subgroup analysis according to MI.

In 1998, a Japanese study including 413 subjects reported that the plasma levels of mono-nitrogen oxides in the *a* allele group (31.2 ± 2.00 μmol/L) were significantly lower than in the *b* allele group (35.5 ± 0.93 μmol/L) \[[@b48-ijms-15-07987]\]. Reduced plasma concentrations of nitrogen oxides (NO) in carriers of the *a* allele were also identified in a study by Rittig *et al.* in a German population \[[@b49-ijms-15-07987]\]. Prevailing experimental and clinical data suggest that decreased NO bioavailability accelerates the progression of atherosclerosis presumably through mechanisms such as platelet activation, vascular smooth muscle proliferation, leukocyte adhesion to the endothelium and increased vascular production of reactive oxygen species \[[@b50-ijms-15-07987],[@b51-ijms-15-07987]\]. Therefore, it is possible that *eNOS 4b/a* gene polymorphisms could contribute to CAD risk by decreasing NO production, which subsequently affects the development of CAD. However, because this variant is located in the intronic region, it is possible that it is in linkage disequilibrium with other functional variants in regulatory regions of the *NOS* gene. In 2002, Wang *et al.* demonstrated that the *eNOS 4a* allele coordinated with the T-786C variant in the promoter region to regulate the transcriptional efficiency of *eNOS* in a haplotype-specific fashion \[[@b52-ijms-15-07987]\]. In 2013, Narne *et al.* reported that the *eNOS 4b/a* polymorphism affected the bioavailability and activity of NO via linkage disequilibrium with T-786C and G894T variants \[[@b25-ijms-15-07987]\]. Consistent with these observations, our meta-analysis revealed that individuals carrying the *eNOS 4a* allele had a higher CAD risk than subjects carrying the *4b* allele.

Our results also suggested that the *4a* allele might be a risk factor for CAD among population-based but not hospital-based subgroups. One explanation for this is that there were differences in the frequency of exposure to risk factors between hospital- and population-based studies. The use of hospital-based population might limit the general applicability of the data. Furthermore, the sample size and number of studies in the hospital-based group might not be sufficient to evaluate potential associations.

In the subgroup analysis according to ethnicity, an increased risk in *4a* carriers was identified among African and Asian populations but not Caucasians. The results could be explained by varying susceptibility of different ethnicities to the *eNOS 4b/a* polymorphism among different ethnicities. Environmental characteristics might also contribute to this discrepancy.

Two previous meta-analyses assessing *eNOS 4b/a* and CAD risk have been performed. In 2004, one study reported an association between *eNOS 4a/a* and ischemic heart disease compared with *eNOS 4b/b* \[[@b10-ijms-15-07987]\]. Although IHD and CAD have overlapping pathogeneses, they are different disease. A second meta-analysis performed in 2010 did not reveal any association between this *eNOS* genetic variant and CAD risk \[[@b11-ijms-15-07987]\]; therefore, our results contradict this study. This could be explained by several reasons. First, different inclusion and exclusion criteria were used. We excluded four studies in which the control population deviated from Hardy-Weinberg equilibrium (HWE) \[[@b53-ijms-15-07987]--[@b56-ijms-15-07987]\]. We also incorporated novel data published between 2010 and October 2013 in our study. Therefore, the number and content of the studies included by Li *et al.* and in the current meta-analysis differed. Second, we performed overall analyses in four genetic models; in contrast Li *et al.* did not perform homozygote comparison and heterozygote comparisons. We also performed subgroup analysis based on ethnicity, the source of the control population, and case sample size to identify all possible associations between *4b/a* polymorphisms and CAD; these factors were not investigated previously.

The present study has some limitations. First, heterogeneity was detected in three genetic models, suggesting that results should be interpreted with caution. Second, most of the included studies were case-control studies, where the cases were survivors of cardiovascular events; those who did not survive were not enrolled. Finally, the sample size in the studies was inadequate. The insufficient sample size might increase the probability of false positives or false negatives.

3.. Experimental Section
========================

3.1.. Literature Search
-----------------------

We systematically searched PubMed using the following medical subject headings (MeSH) or search terms: ("CHD" OR "atherosclerosis" OR "coronary atherosclerosis" OR "aortic atherosclerosis" OR "coronary heart disease" OR "coronary artery disease" OR "coronary disease" OR "myocardial infarction" OR "MI" OR "acute coronary syndrome") and ("polymorphism\*" OR "variation") and ("eNOS" OR "endothelial nitric oxide synthase"). The search covered all English language publications within a range of published years from 1996 to 2013 (the last search was performed on 31 October 2013). The bibliographies of previous meta-analyses and published reviews were also checked for additional relevant publications.

3.2.. Inclusion and Exclusion Criteria
--------------------------------------

The inclusion criteria for studies were as follows: (1) independent case-control, cohort or cross-sectional studies; (2) studies that evaluated the association between *eNOS* intron *4b/a* variable number of tandem repeats (VNTR) polymorphisms and CAD susceptibility; (3) studies that provided complete data regarding genotype number and allele frequencies; (4) studies in which CAD was diagnosed based on coronary angiography as well as clinical criteria with clearly reported details; (5) studies that also included controls demonstrated to lack CAD either by coronary arteriography or by clinical criteria; and (6) studies that were published in English. The exclusion criteria were as follows: (1) insufficient data regarding genotypes and allele frequencies; (2) unconfirmed diagnosis of CAD; (3) the genotype distribution of the control population did not conform to HWE; and (4) overlapping publications.

3.3.. Data Extraction
---------------------

Two researchers (Y.Y. and K.D.) extracted information including the first author, year of publication, country, ethnicity of the study population, source of controls, genotype number in cases and controls, HWE in controls and study outcome. Data were extracted separately and compared to reach a consensus. Different ethnicities were categorized as Asians and non-Asians (Caucasians, Africans, or others). Different ethnic descents in one study were considered to be independent studies when subanalyses based on ethnicity were performed.

3.4.. Statistical Analysis
--------------------------

The association between *eNOS 4b/a* gene polymorphisms and CAD was compared using the odds ratio (OR) corresponding to a 95% confidence interval (95% CI). We used four different genetic models in our analysis: homozygote comparison (*aa vs. bb*), heterozygote comparison (*ab vs. bb*), dominant (*aa* + *ab vs. bb*), and recessive models (*aa vs. ab* + *bb*).

Heterogeneity between studies was assessed using *p* values for the Q statistic and *I*^2^ values. Significance was set at the *p* \< 0.1 level; *p* \< 0.1 for the Q test indicated there was heterogeneity across the studies and *p* \> 0.1 for the *Q* test indicated a lack of heterogeneity among studies. The random-effects model was used to estimate the pooled OR according to the DerSimonian and Laird method \[[@b57-ijms-15-07987]\]. *I*^2^ was calculated to describe the percentage of variation caused by the heterogeneity: 0%--25%, no heterogeneity; 25%--50%, moderate heterogeneity; 50%--75%, large heterogeneity; and 75%--100%, extreme heterogeneity).

To determine the source of heterogeneity across studies, logistic meta-regression analyses were performed. Publication year, population ethnicity, source of the control group, outcome, total sample size, case sample size, control sample size, and the ratio of case size to control size were examined to evaluate the extent to which different variables explained any observed heterogeneity. Stratified analyses were also performed for ethnicity, source of controls, and case sample size. Sensitivity analyses were conducted by removing each study individually and consecutively from the combined data set. Re-analysis of the remaining studies, allowed the robustness of the main findings to be tested. In addition, a funnel plot was used to estimate the potential publication bias; Begg's and Egger's tests were then used to examine funnel plot asymmetry with significance set at *p* \< 0.05, and the trim and fill method was performed when bias was detected. STATA 12.0 software was used to perform all statistical analyses (StataCorp, College Station, TX, USA).

4.. Conclusions
===============

In conclusion, the results of the current meta-analysis suggested that *eNOS 4b/a* polymorphisms could increase the risk of CAD, particularly in African populations and among the population-based studies. Further studies with larger sample sizes should be performed to confirm these findings.
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###### 

Study Characteristics of genotypes in coronary artery disease (CAD) cases and controls in the analysis of endothelial nitric oxide synthase (*eNOS*) *4b/a* polymorphism.

  Author                              Year   Country       Ethnicity            Source of controls   End points   Sample size   Genotype distribution                               
  ----------------------------------- ------ ------------- -------------------- -------------------- ------------ ------------- ----------------------- ---- ----- ----- ---- ----- -----
  Wang *et al.*                       1996   Australia     Caucasian            PB                   CAD          153           549                     1    50    102   18   122   409
  Hibi *et al.*                       1998   Japan         Asian                PB                   AMI          357           226                     5    68    284   4    48    174
  Ichihara *et al.*                   1998   Japan         Asian                HB                   MI           550           455                     7    97    446   9    107   339
  Odawara *et al.*                    1998   Japan         Asian                HB                   CHD          122           42                      0    19    103   0    11    31
  Hooper *et al.*                     1999   American      African              PB                   MI           185           110                     15   68    102   14   52    44
  Nakagami *et al.*                   1999   Japan         Asian                HB                   CAD          34            40                      1    9     24    1    18    21
  Park *et al.*                       2000   Korea         Asian                PB                   AMI          206           121                     1    49    156   5    23    93
  Fowkes *et al.*                     2000   UK            Caucasian            PB                   CHD          300           137                     5    64    231   4    37    96
  Pulkkinen *et al.*                  2000   Finland       Caucasian            PB                   CHD          110           308                     5    26    79    9    96    203
  Sigusch *et al.*                    2000   Germany       Caucasian            HB                   CHD          413           625                     11   115   287   12   159   454
  Granath *et al.*                    2001   Australia     Caucasian            PB                   CAD          620           567                     14   158   448   11   138   418
  Alvarez *et al.*                    2001   Spain         Caucasian            PB                   CAD          300           170                     6    72    222   2    37    131
  Hwang *et al.*                      2002   Taiwan        Asian                HB                   CAD          70            149                     0    14    56    1    32    116
  Gardemann *et al.*                  2002   Germany       Caucasian            PB                   MI           528           1265                    13   144   371   25   306   934
  Cine *et al.*                       2002   Turkey        other                PB                   MI           306           207                     2    55    249   9    55    143
  Park *et al.*                       2004   Korea         Asian                HB                   ACS          142           164                     7    30    105   4    21    139
  Agema *et al.*                      2004   Netherlands   Caucasian            PB                   CAD          466           752                     8    77    381   12   195   545
  Letonja *et al.*                    2004   Slovenia      Caucasian            PB                   CAD          109           151                     6    30    73    6    41    104
  Fatini *et al.*                     2004   Italy         Caucasian            PB                   ACS          537           477                     14   138   385   24   138   315
  Milutinovic *et al.*                2005   Slovenia      Caucasian            NM                   CAD          188           215                     10   58    120   11   60    144
  Rao *et al.*                        2005   America       Caucasia + African   HB                   CAD          50            144                     1    17    32    6    40    98
  Matyar *et al.*                     2005   Turkey        other                HB                   CAD          133           133                     1    35    97    5    47    81
  Salimi *et al.*                     2006   Iran          other                NM                   CAD          158           141                     1    29    128   3    41    97
  Agirbasli *et al.*                  2006   Turkey        other                HB                   CAD          100           100                     0    21    79    4    21    75
  Kim *et al.*                        2007   Korea         Asian                PB                   CAD          211           147                     0    40    171   2    35    110
  Rios *et al.*                       2007   Brazil        Caucasia + African   HB                   CAD          267           323                     12   90    165   18   101   204
  Sampaio *et al.*                    2007   Brazil        other                HB                   AMI          103           115                     4    32    67    4    29    82
  Vasilakou *et al.*                  2008   Greece        Caucasian            PB                   CAD          161           209                     5    39    117   9    60    140
  Meluzin *et al.*                    2009   Czech rep     Caucasian            HB                   CAD          89            321                     0    26    63    10   103   208
  Kincl *et al.*                      2009   Czech rep     Caucasian            HB                   CAD          222           939                     9    63    150   35   272   632
  Bae *et al.*                        2010   Korea         Asian                PB                   CAD          196           192                     0    35    161   2    42    148
  Gururajan *et al.*                  2010   India         Asian                NM                   ACS          100           106                     4    19    77    12   36    58
  Jaramillo *et al.*                  2010   Chile         other                PB                   CAD          112           112                     1    16    95    3    12    97
  Jemaaa *et al.*                     2012   Tunisia       African              PB                   MI           250           310                     4    61    185   15   105   190
  Da Costa Escobar Piccoli *et al.*   2012   Brazil        other                PB                   ACS          108           132                     6    34    68    14   31    87
  Kallel *et al.*                     2013   Tunisia       African              PB                   MI           225           303                     3    58    164   15   101   187
  Narne *et al.*                      2013   India         Asian                HB                   CAD          121           160                     2    42    77    5    50    105

Abbreviations: eNOS, endothelial nitric oxide synthase; HB, hospital-based; PB, population-based; NM, not mentioned; OR, odds ratios; CI, confidence intervals; CAD, coronary artery disease; CHD, coronary heart disease; MI, myocardial infarction; AMI, acute myocardial infarction; and ACS, acute coronary syndrome.

###### 

Pooled odds ratios (OR) and 95% confidence intervals (CI) of the association between *eNOS 4b/a* polymorphism and CAD.

  Total and subgroups     Studies   Homozygote comparison (*aa vs. bb*)   Heterozygote comparison (*ab vs. bb*)   Dominant model (*aa* + *ab vs. bb*)   Recessive model (*ab* + *bb vs. aa*)                                                                                     
  ----------------------- --------- ------------------------------------- --------------------------------------- ------------------------------------- -------------------------------------- --------- ------ ------------------- --------- ------ ------------------- ------- ------
  Total                   37        1.47 (1.16--1.87)                     0.085                                   25.5                                  1.14 (1.02--1.27)                      \<0.001   56.7   1.18 (1.06--1.33)   \<0.001   61.1   0.72 (0.58--0.89)   0.213   15.4
  MI                      6         2.30 (1.17--4.51)                     0.020                                   62.6                                  1.42 (1.07--1.89)                      0.002     74.2   1.50 (1.09--2.07)   \<0.001   80.7   0.56 (0.39--0.82)   0.054   54.1
                                                                                                                                                                                                                                                                                 
  **Ethnicity**                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                 
  Caucasian               16        1.03 (0.80--1.31)                     0.621                                   0.0                                   1.04 (0.90--1.20)                      0.006     53.3   1.04 (0.91--1.19)   0.007     53.0   0.98 (0.77--1.25)   0.679   0.0
  Asian                   11        1.82 (1.03--3.20)                     0.316                                   13.8                                  1.21 (0.96--1.54)                      0.027     50.5   1.26 (0.99--1.61)   0.011     56.3   0.60 (0.36--0.99)   0.434   0.4
  African                 5         2.93 (1.71--5.03)                     0.821                                   0.0                                   1.46 (1.16--1.83)                      0.353     9.4    1.58 (1.27--1.96)   0.370     6.5    0.41 (0.24--0.70)   0.684   0.0
  Other                   7         2.65 (1.37--5.13)                     0.369                                   7.8                                   1.17 (0.84--1.62)                      0.033     56.4   1.29 (0.94--1.77)   0.033     56.3   0.39 (0.21--0.71)   0.511   0.0
                                                                                                                                                                                                                                                                                 
  **Source of control**                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                 
  HB                      14        1.11 (0.78--1.56)                     0.509                                   0.0                                   1.04 (0.88--1.23)                      0.072     38.2   1.07 (0.89--1.27)   0.027     46.8   0.90 (0.64--1.26)   0.613   0.0
  PB                      20        1.64 (1.18--2.27)                     0.070                                   33.9                                  1.16 (1.00--1.35)                      \<0.001   61.8   1.21 (1.05--1.40)   \<0.001   63.4   0.65 (0.48--0.89)   0.113   28.7
  NM                      3         2.05 (0.66--6.32)                     0.111                                   54.4                                  1.54 (0.80--2.98)                      0.011     77.6   1.63 (0.80--3.30)   0.003     82.6   0.58 (0.24--1.40)   0.232   31.6
                                                                                                                                                                                                                                                                                 
  **Case size**                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                 
  \>500                   6         0.88 (0.62--1.24)                     0.666                                   0.0                                   0.96 (0.74--1.25)                      \<0.001   78.7   0.97 (0.76--1.22)   0.001     75.9   1.14 (0.80--1.60)   0.642   0.0
  \<500                   31        1.75 (1.35--2.28)                     0.262                                   13.2                                  1.20 (1.07--1.35)                      0.011     40.7   1.26 (1.11--1.42)   0.002     48.0   0.61 (0.48--0.77)   0.453   0.8
                                                                                                                                                                                                                                                                                 
  **Control size**                                                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                 
  \>500                   4         1.21 (0.72--2.05)                     0.138                                   45.6                                  1.07 (0.85--1.36)                      0.024     68.3   1.09 (0.84--1.42)   0.007     75.1   0.84 (0.52--1.34)   0.214   33.1
  \<500                   33        1.56 (1.19--2.05)                     0.113                                   23.9                                  1.15 (1.01--1.31)                      \<0.001   55.6   1.20 (1.06--1.36)   \<0.001   59.0   0.68 (0.53--0.88)   0.233   14.8

Abbreviations: eNOS, endothelial nitric oxide synthase; OR, odds ratios; CI, confidence intervals; MI, myocardial infarction; HB, hospital-based; PB, population-based; and NM, not mentioned.

[^1]: These authors contributed equally to this work.
